Exos Asset Management’s CONMED CNMD Stock Holding History

Exos Asset Management’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-647	Closed	-$89K	–	515
2021 Q2	$89K	Buy	+647	New	+$88.6K	0.05%	357

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Exos Asset Management's CNMD Position: Q3 2021 in Review

Exos Asset Management sold out of CONMED (CNMD) in Q3 2021, closing a stake of 647 shares — an estimated $89K sold.

Exos Asset Management first reported a position in CNMD in Q2 2021 and held it in 1 quarter. The position peaked at $89K in Q2 2021. 262 funds tracked by Wall St. Rank hold CNMD as of Q3 2021.

Exos Asset Management reported no remaining CONMED position as of Q3 2021 after selling out during the quarter.
Exos Asset Management sold 647 CONMED shares in Q3 2021, an estimated $89K.
Exos Asset Management first reported a position in CONMED in Q2 2021 and held it in 1 quarter.
Exos Asset Management's CONMED position peaked at $89K in Q2 2021.
262 funds tracked by Wall St. Rank held CONMED as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.